Newly Diagnosed With Pancreatic Cancer: First Steps

For most cancers, stage drives everything. Pancreatic cancer works differently in the first two weeks. The question your team is racing to answer is whether the tumor can be removed.

NCI sorts patients into four groups:

• Resectable. No involvement of nearby blood vessels.
• Borderline resectable. Vessels or nearby structures are involved enough that a complete removal is at risk.
• Locally advanced. Local invasion, mostly of blood vessels, rules out surgery.
• Metastatic. Cancer has spread beyond the pancreas.

The vessels that decide this are named. The superior mesenteric artery, the celiac axis, the superior mesenteric vein, and the portal vein all run near or through the field a surgeon must clear. Ask which of those four your scan mentions, and how much of each is touched.

The stakes are high. NCI reports that for localized disease with small cancers under 2 cm and no lymph node spread, complete surgical removal is associated with an actuarial 5-year survival rate of 18 to 24 percent. That group is less than 20 percent of cases.

An ordinary abdominal CT is not sufficient for this decision. NCI describes the workup as using helical CT, MRI, and endoscopic ultrasonography, which puts an ultrasound probe on the end of a scope right next to the pancreas. These studies exist to judge resectability and to find disease that rules surgery out.

If your imaging was done at an outside facility, ask whether it followed a pancreas-specific protocol. Repeating a scan is far less costly than planning around an inadequate one.

NCI is blunt here: no tumor-specific markers exist for pancreatic cancer.

CA 19-9 has low specificity. Most patients with pancreatic cancer have an elevated level at diagnosis, which sounds useful until you consider how many other conditions raise it. NCI also states that a normal CA 19-9 level does not rule out recurrence.

Treat it as a trend line, not a verdict. Ask for the value at diagnosis so later readings have something to be compared against.

One more staging tool worth knowing about. Peritoneal cytology, which samples fluid from the abdominal cavity, has a positive predictive value of 94 percent and specificity of 98 percent for determining that a tumor is unresectable. Its sensitivity is only 25 percent, so a negative result proves little.

This is the most actionable fact in the entire workup.

NCI puts operative mortality for pancreatic resection between 1 and 16 percent. The spread is not random. The 16 percent figure comes from low-volume centers, while high-volume centers run about 4 percent.

Ask the surgeon how many pancreaticoduodenectomies the center performs each year. That operation, called the Whipple procedure, is used for tumors in the head of the pancreas. Distal pancreatectomy handles tumors of the body and tail. Total pancreatectomy is used when clear margins require it.

After surgery. The PRODIGE-24 trial compared FOLFIRINOX against gemcitabine. Median disease-free survival was 21.4 months versus 12.8 months. Median overall survival was 53.5 months versus 35.5 months. The cost was real toxicity: grade 3 or 4 side effects in 75.9 percent of the FOLFIRINOX group against 52.9 percent with gemcitabine.

A gentler option. ESPAC-4 tested gemcitabine plus capecitabine. Median overall survival was 28.0 months against 25.5 months for gemcitabine alone, and estimated 5-year survival rose from 16.3 percent to 28.8 percent.

Before surgery. Two trials support treating first and operating later. A021501 gave modified FOLFIRINOX for borderline resectable disease and reported median overall survival of 29.8 months with a 43 percent rate of microscopically clear margins. PREOPANC compared chemoradiation before surgery against surgery first, and found a 5-year survival rate of 20.5 percent versus 6.5 percent.

You may also see S-1 mentioned. The Japanese JASPAC-01 trial showed a 5-year survival of 44.1 percent with S-1 against 24.4 percent with gemcitabine, but S-1 is not approved by the FDA in the United States.

FOLFIRINOX contains fluorouracil, and capecitabine turns into it in the body. Both are fluoropyrimidines.

NCI estimates that 1 to 2 percent of people carry germline pathogenic variants in DPYD, the gene for the enzyme that clears these drugs. Without that enzyme working normally, a standard dose behaves like an overdose. Depending on genotype, NCI notes that avoiding fluoropyrimidines or cutting the dose by 50 percent may be recommended.

The test costs less than $200, though NCI notes insurance coverage varies. Ask about it before the first cycle, not after a severe reaction.

Three interventions belong in the first conversations.

Bile duct blockage. Jaundice, light stools, and dark urine mean the duct is obstructed. NCI describes surgical or radiological biliary decompression and stenting to relieve it.

Digestion. When the pancreas cannot supply enough digestive enzymes, food passes through unabsorbed. Pancreatic enzyme replacement therapy addresses this. Weight loss that continues despite eating is the signal.

Pain. NCI notes that celiac axis and intrapleural nerve blocks can provide highly effective and long-lasting pain control for some patients. This is a procedure, not a pill, and it is worth asking about early.

NCI lists a family history of pancreatic cancer as a risk factor, along with genetic conditions tied to the BRCA1, BRCA2, PALB2, and ATM genes.

Ask for a referral to genetic counseling. The answer can matter for treatment selection and for your siblings and children.

The 67,530 new cases and 52,740 deaths projected for the United States in 2026 are American Cancer Society estimates, which NCI republishes. Pancreatic cancer is the fourth leading cause of cancer death in men and the third in women.

SEER reports 5-year relative survival of 13.7 percent among people diagnosed between 2016 and 2022, and breaks it out by how far the cancer had spread at diagnosis:

• Localized, 15 percent of cases, 43.6 percent survival.
• Regional, 28 percent of cases, 17.0 percent.
• Distant, 51 percent of cases, 3.4 percent.

Half of patients are diagnosed after the cancer has already spread. That is the reason the resectability question comes first.

• Ask which resectability category you are in, and which vessels are involved.
• Confirm the CT followed a pancreas-specific protocol.
• Get your baseline CA 19-9 value and date.
• Ask the surgical center its annual volume for this operation.
• Request DPYD testing before any fluorouracil or capecitabine.
• Ask whether jaundice needs a stent before treatment starts.
• Ask about enzyme replacement if you are losing weight.
• Request genetic counseling.

A blocked bile duct is the complication most likely to turn urgent while you are still deciding on treatment.

• Call 911 or go to an emergency department if yellow skin or eyes come with a temperature of 100.4°F (38°C) or higher, shaking chills, and pain in the upper right or upper middle of your abdomen. MedlinePlus describes that pattern as infection in the blocked duct, which can tip into sepsis. Confusion or feeling faint alongside it makes it more urgent, not less.
• Call your care team the same day if your eyes or skin start to yellow, your urine darkens, or your stools go pale. That is the duct closing off, and stenting is the answer.
• Call your care team within a day or two if you keep losing weight despite eating, your stools are greasy and hard to flush, or belly and back pain is outrunning the painkillers you have. Enzyme replacement and a nerve block are both worth raising early.

• https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq
• https://seer.cancer.gov/statfacts/html/pancreas.html
• https://medlineplus.gov/ency/article/000290.htm
• https://www.cancer.org/research/cancer-facts-statistics.html